营养药配方和天然化合物用于治疗慢性疾病
Ghizal Fatima1,2, Sadaf Khan1,2, Vani Shukla2
1Department of Biotechnology, Era University, Lucknow, India.
Frontiers in nutrition
|October 31, 2025
概括
来自自然来源的营养药物,通过向炎症和氧化应激,在治疗慢性疾病方面表现有前途. 先进的交付系统和严格的验证是它们融入医疗保健的关键.
科学领域:
- 综合医学和天然产品化学.
- 药理学和分子生物学.
- 营养科学与公共卫生.
背景情况:
- 慢性非传染性疾病 (NCD) 给全球健康带来了重大挑战,传统的治疗方法往往只能控制症状,而不是逆转疾病的进展.
- 营养药,来自自然来源的生物活性化合物,具有抗炎,抗氧化和免疫调节性质,为非传染性疾病提供潜在的治疗益处.
- 目前的研究综合了关于营养药分子机制和治疗应用的证据,解决了生物可用性和输送方面的局限性.
研究的目的:
- 审查当前关于营养保健品有效性和分子机制在管理主要慢性疾病的证据.
- 分析先进的传递技术,提高营养药物生物可用性和向性.
- 讨论挑战,并提出未来的方向,以营养药整合到医疗保健.
主要方法:
- 系统审查关于营养药的科学文献,它们的机制和治疗应用.
- 对纳米配方和封装等先进的输送系统的证据分析.
- 讨论监管,安全和标准化的障碍.
主要成果:
- 关键的营养药类 (多,黄,欧米茄-3脂肪酸,益生菌,类) 通过氧化应激缓解和免疫调节等机制显示出潜力.
- 先进的输送技术在改善营养药物生物可用性和有针对性的输送方面显示出前景.
- 仍然存在重大障碍,包括监管不一致,安全问题和标准化需求.
结论:
- 营养药品为慢性疾病管理提供了一个有希望的,基于证据的辅助或替代方案.
- 严格的临床验证,质量控制和安全监测对于广泛采用至关重要.
- 未来的方向包括个性化策略,人工智能驱动的发现和全球监管协调.
更多相关视频
相关概念视频
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
262
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
262
01:28Biopharmaceutics and Pharmacokinetics: Overview
3.2K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.2K
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
212
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
212
01:26Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
01:27Bioavailability Enhancement: Drug Permeability Enhancement
163
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
163
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
127
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
127